Fas/APO-1 is a cell surface protein known to trigger apoptosis upon specific antibody engagement. Because wild-type p53 can activate transcription as well as induce apoptosis, we queried whether p53 might upregulate Fas/APO-1. To explore this possibility, we examined human p53-null (H358 non-small-cell lung adenocarcinoma and K562 erythroleukemia) and wild-type p53-containing ( 
The wild-type p53 tumor suppressor can inhibit cellular proliferation, eliminate tumorigenicity (4, 16, 19, 23, 40, 43, 44, 77) , and suppress gene amplification and oncogene-mediated cellular transformation. The p53 protein is a transcriptional regulator (22, 57) that can directly bind to DNA sequencespecific sites (9, 17, 20, 26, 34-36, 61, 80, 82, 84) or interact with other transcriptional regulatory factors such as Sp1 (7) and the CCAAT-binding factor (2) . Genes known to be positively regulated by wild-type p53 include the WAF1/Cip1 gene, which encodes an inhibitor of cyclin-dependent kinase (18, 28) , the growth arrest and DNA damage-inducible gene GADD45 (34) , the muscle-type creatine kinase gene MCK (72) , the putative proto-oncogene mdm-2 (5), the epidermal growth factor receptor gene (15) , and the recently identified bax protein-encoding gene (46, 50) .
The studies of the effect of wild-type p53 on cellular growth and death have led to the view of p53 as a ''guardian of the genome'' (38) . p53 protein levels increase in response to DNAdamaging agents such as ionizing radiation and result in the delay of cell cycle progression from G 1 into S phase to allow for repair of DNA damage (33, 34) . If DNA repair is unsuccessful, programmed cell death (apoptosis) occurs. Although wild-type p53 is known to be involved in the initiation of apoptosis following exposure to etoposide or DNA-damaging ionizing radiation (12, 41) , p53-driven programmed cell death is not always dependent upon DNA strand damage. For example, overexpression of exogenous wild-type p53 in cells deficient for p53 expression is also known to lead to apoptosis (32, 54, 56, 60, 62, 70, 79) . The mechanism(s) by which p53 orchestrates diverse cellular programs ultimately culminating in apoptotic cell death is the subject of intense investigation. Because p53-dependent apoptosis can occur in the absence of p53 target gene activation, Caelles et al. (8) have proposed that p53 may function to repress cellular survival genes such as bcl-2 (46) or participate in the enzymatic machinery involved in intranucleosomal cleavage of DNA (38, 76) . It is conceivable, however, that p53 can also transcriptionally activate unidentified target genes which can mediate apoptosis.
Fas/APO-1, a member of the tumor necrosis factor receptor superfamily expressed on the cell surface of normal and malignant cells, can transduce a signal for apoptosis upon specific ligand or antibody engagement (31, 49, 64, 68, 78) . Previous investigations with mice homozygous for the lpr or gld mutations have established the biologic relevance of the Fas/Fas ligand system in autoimmune disease pathogenesis. In both cases, mice develop circulating autoantibodies, glomerulonephritis, and lymphadenopathies (13) . The autoimmune phenotype arising as a consequence of the lpr mutation appears to result from a loss of Fas function (1, 11, 71, 74) and can be reversed in mice reconstituted with functional Fas under the control of a CD2 promoter (75) . Reciprocally, autoimmune disease in gld mice appears to result from the loss of a functional Fas ligand (67) . Programmed cell death induced by Fas/Fas-ligand has been implicated in the killing of tumor targets by immune cytotoxic effector cells (27, 58, 63, 69) and in the elimination of chronically activated lymphocytes at the periphery by a mechanism known as activation-induced apoptosis (3, 48, 59, 75) . However, the spectrum of Fas/Fas ligandinduced apoptosis is unlikely to be unique to the immune system, because these proteins are expressed in a variety of normal and malignant nonhematopoietic tissues (39, 51, 52, 64, 78) .
To test the hypothesis that the p53 can transcriptionally activate Fas/APO-1 expression, we have investigated the effects of exogenous p53 on Fas/APO-1 expression in human tumor cell lines either homozygously deleted for the p53 allele or expressing wild-type p53. We now report that the introduction of either wild-type or a temperature-sensitive mutant of human p53, Ala-143, (83) can (at the permissive temperature) enhance expression of the Fas/APO-1 gene. Induction of Fas/ APO-1 mRNA does not require de novo protein synthesis. These observations provide the first evidence that p53 can directly regulate the expression of an extracellular membranebound protein potentially involved in the induction of apoptotic cell death.
full-length human wild-type p53 gene (4); (ii) a 1.3-kb PstI gene fragment corresponding to rat glyceraldehyde-3-phosphate-dehydrogenase (GAPDH) (24) ; and (iii) a 1.4-kb EcoRI fragment corresponding to nucleotides 336 to 1806 of human Fas/APO-1 (31) . Each DNA fragment was purified by agarose gel electrophoresis, recovered with GeneClean (Bio 101, La Jolla, Calif.), and radiolabeled by the random-primer technique with ␣-32 P-labeled deoxyribonucleoside triphosphates (21) .
For temperature shift experiments, cell lines were cultured at the permissive temperature (32.5ЊC) overnight. Where indicated, cycloheximide (10 g/ml) was added 30 min prior to the temperature shift. For the determination of mRNA half-life, cell lines were cultured at 32.5 or 37.5ЊC overnight, actinomycin D (20 g/ml) was added, and mRNA was isolated sequentially at the times indicated. Fas/APO-1 mRNA levels were quantified in the linear range of the X-ray film on a personal densitometer (Molecular Dynamics, Sunnyvale, Calif.) with the Image Quant software program. Each sample measurement was calculated as a ratio of the average area of the Fas/APO-1 transcript and the control 1.3-kb GAPDH transcript.
Nuclear run-on transcription assays. A total of 2.5 ϫ 10 7 to 5 ϫ 10 7 Ala-143 K562 or K562 parental (par) cells were harvested after an overnight culture at the permissive or nonpermissive temperature. Nucleus preparation and in vitro transcription were carried out as described previously (73) with the following modifications. Following DNase and proteinase K treatments, the nuclear RNA was isolated by phenol-chloroform-isoamyl alcohol extraction and ammonium acetate precipitation. For the reaction shown, [ 32 P]RNA was normalized to the lowest sample to achieve 10 7 cpm/ml of hybridization buffer. Hybridization buffer consisted of 50% formamide, 5ϫ SSC (pH 7.0) (1ϫ SSC is 0.15 M NaCl plus 0.015 M sodium citrate), 5ϫ Denhardt's solution, 1% SDS, 10 mM sodium phosphate (pH 7.0), 1 mM sodium PP; (pH 7.0), and 100 g of yeast tRNA per ml. After hybridization for 72 h, the filters were washed in 2ϫ SSC at 65ЊC, then in 2ϫ SSC containing 10 g of RNase A per ml at 25ЊC, and finally in 2ϫ SSC containing 0.1% SDS at 65ЊC. For the hybridization, 5 g of Fas/APO-1 cDNA (described above), purified pGEM 11zf(ϩ) vector (Promega, Madison, Wis.), and human transferrin receptor cDNA (American Type Culture Collection) were denatured and slot blotted. For the experiment shown in Fig. 7 , the dried filters were exposed to X-ray film overnight. The relative transcription rate was determined as a ratio of the average area of the Fas/APO-1 signal to transferrin receptor signal obtained with a Phosphor Imager (Molecular Dynamics) with the Image Quant software program. 
RESULTS
Wild-type or temperature-sensitive mutant p53 regulates expression of Fas/APO-1 in human tumor cell lines. To determine whether exogenous p53 can alter Fas/APO-1 expression, the human non-small cell lung adenocarcinomas H358 and H460 were transduced with wild-type p53 in an adenovirus expression construct under the control of a cytomegalovirus promoter. H358 cells are deficient in p53 expression as a result of a deletion in p53-specific gene sequences, whereas H460 cells contain an endogenous wild-type p53 gene (45, 66) . Previous studies in our laboratories have demonstrated that adenovirus transfer was highly efficient and that expression of p53 reached maximal levels 48 h after infection (14, 25) . As shown in Fig. 1 , Fas/APO-1 expression was markedly enhanced in both H358 and H460 cells transduced with wild-type p53 (Adp53) compared with parental cells and vector control (Ad-luc) at 48 h. A 2.9-to 3.7-fold increase in the mean fluorescence intensity (MFI) of cell surface Fas/APO-1 expression, representative of antigenic density on a per-cell basis, was observed in both cell lines after p53 introduction (average of three experiments). In the experiment shown, introduction of the Ad-luc vector alone in both H358 and H460 cells resulted in an increased percentage of cells positive for Fas/APO-1 expression compared with the parental cells. It is important to note, however, that Fas/APO-1 density (MFI) was significantly increased only after transduction with the p53-containing construct. To further explore Fas/APO-1 upregulation by p53, we examined the effects of a temperature-sensitive p53 mutant, Ala-143, stably transfected into p53-null K562 cells (37, 83 (Fig. 5 ). These observations demonstrate that Fas/APO-1 is expressed throughout the cell cycle and that elevations in Fas/ APO-1 protein levels are not solely related to an altered cell cycle profile in Ala-143 K562 cultured at the permissive temperature.
Increased Fas/APO-1 mRNA levels in Ala-143 K562 cells cultured at 32.5؇C are independent of de novo protein synthesis. Increased cell surface Fas/APO-1 in Ala-143 K562 cells cultured at 32.5ЊC is probably the result of elevated mRNA levels in these cells. To validate this possibility, mRNA harvested from Ala-143 K562 cells cultured at either 37.5 or 32.5ЊC for 16 h was examined by Northern blot analysis. As shown in Fig. 6 , a Fas/APO-1-specific probe hybridized to a 2.5-and 1.9-kb transcript in the Ala-143 K562 cell line, consistent with previous observations in other cell types (31) . No Fas/APO-1 transcripts were observed in K562 par cultured at either temperature (Fig. 6, lanes A and B) . Interestingly, Fas/ APO-1 transcripts were present in Ala-143 K562 cells maintained at both 37.5 and 32.5ЊC despite the absence of detectable Fas/APO-1 protein in cells cultured at 37.5ЊC (Fig. 2 and  3) . Both Fas/APO-1 transcript types, however, were present at higher levels in Ala-143 K562 cells maintained at 32.5ЊC than in cells cultured at the nonpermissive temperature of 37.5ЊC (Fig. 6, compare lanes E and F) . A similar temperature downshift failed to enhance Fas/APO-1 mRNA in His-273 K562 cells (lanes C and D). These data demonstrate that temperature-sensitive transcriptional activation of Ala-143 is associated with enhanced Fas/APO-1 mRNA accumulation. (Fig. 6 , lanes G and H and lanes I and J, respectively). Importantly, Ala-143 K562 cells incubated with cycloheximide prior to the temperature downshift showed an increase in Fas/APO-1 mRNA levels similar to that of identical cultures maintained at 32.5ЊC in the absence of the drug (compare lanes F and L). A positive effect of cycloheximide on Fas/APO-1 mRNA levels was observed at the permissive temperature, suggesting the potential for a short-lived transcriptional repressor or other regulatory proteins involved in mRNA degradation. Alterations in Fas mRNA half-life alone are unlikely to contribute to the observed enhancement of Fas/APO-1 mRNA in cycloheximide-treated Ala-143 K562 cells cultured at 32.5ЊC, because elevated transcript levels were not present in similarly treated cells cultured at 37.5ЊC (compare lanes E and K) and mRNA half-lives were not found to differ in cycloheximide-treated and untreated Ala-143 cells maintained at 32.5 versus 37.5ЊC (see below). The same blot was rehybridized with probes specific for human p53 and GAPDH to verify expression and loading efficiency, respectively. Collectively, these results suggest a primary requirement for transcriptional activation, a lack of dependence on de novo protein synthesis, and a possible direct involvement of p53 in the upregulation of Fas/APO-1 mRNA.
Transcriptional enhancement of Fas/APO-1 mRNA in Ala-143 K562 cells. To verify that Fas/APO-1 mRNA accumulation resulted from transcriptional activation of the Fas/APO-1 gene in K562 cells, nuclear run-on assays were performed. For these experiments, K562 par or Ala-143 K562 cells were incubated overnight at the permissive or nonpermissive temperature and their nuclei were harvested for in vitro analysis of transcriptional rate. As shown in Fig. 7 , transcriptional activation of the Fas/APO-1 gene was not demonstrable in K562 par cells cultured at either temperature; transcription of the transferrin receptor, however, was easily detectable. Induction of Fas/ APO-1 transcription was observed in Ala-143 K562 cells maintained at either 32.5 or 37.5ЊC, corroborating results of our previous Northern blot analyses (Fig. 6) . Somewhat surprisingly, however, in three experiments the specific rate of Fas/ APO-1 mRNA synthesis (normalized for transferrin expression) increased only 1.4-fold in Ala-143 K562 cultured at 32.5ЊC compared with 37.5ЊC. To rule out differences in Fas/ To determine the sensitivity of the Ala-143 K562 cells to anti-Fas-mediated apoptosis, cells maintained at 32.5 or 37.5ЊC were cultured overnight in the presence of 0.5 g of anti-Fas per ml or isotypematched control antibody before assessment of cellular metabolic function by MTT reduction as described previously (51) . As controls, the Fas/APO-1-positive Jurkat E6 lymphoid cell line and the Fas/APO-1-negative K562 par and His-273 K562 cells were also examined. Results from one of three experiments are shown in Fig. 9 . Neither the K562 par, the His-273, nor the Ala-143 K562 cells cultured at either the permissive or nonpermissive temperature demonstrated a significant metabolic inhibition after anti-Fas treatment. As expected, Jurkat cells were consistently inhibited by Ͼ80%. Further, Ala-143 K562 cells were unaffected by anti-Fas treatment as measured by cellular survival studies or flow-cytometric DNA fragmentation analyses (data not shown). These results demonstrate that despite cell surface Fas/APO-1 expression, Ala-143 K562 cells are refractory to anti-Fas-mediated signaling for cell death. Interestingly, K562 cells are known to be resistant to a variety of apoptotic stimuli as a result of their expression of the Bcr-Abl fusion protein (42) .
DISCUSSION
We have presented data showing that expression of the Fas/APO-1 gene product, a cell surface protein known to trigger apoptosis, can be positively regulated by p53 in both p53-deleted and wild-type p53-containing human cell lines. These observations provide the first demonstration, to our knowledge, that p53 can activate a gene known to be involved in the initiation of apoptosis.
The Fas/APO-1 protein was initially characterized by its ability to trigger programmed cell death in a variety of normal and malignant cell types upon monoclonal antibody binding (31, 49, 51, 52, 68, 78) . Although Fas/APO-1 expression can be induced or upregulated in response to cellular activation or various cytokines (52, 68, 78) , there is no available information concerning the molecular events underlying this process. In this report, we document that the Fas/APO-1 gene is a transcriptional target of the tumor suppressor gene p53. Using wild-type p53 transduced into H358 or H460 cells or the human temperature-sensitive p53 mutant Ala-143 stably transfected into K562, we demonstrated that Fas/APO-1 can be markedly induced or upregulated. We have previously demonstrated that the Ala-143 p53 mutant can assume a p53 wildtype-like conformation; Ala-143 has a conformation recognized by monoclonal antibody PAb1620 at 32.5 but not 37.5ЊC. This mutant also potently activates reporter constructs containing the p53CON and ribosomal gene cluster elements at the endogenous WAF1/Cip1 gene, while the parental K562 and other non-temperature-sensitive p53 mutants (His-175, Trp-248, His-273, and Gly-281) fail to activate p53-driven transcription (83) . Taken together, these studies suggest that induction of Fas/APO-1 is tightly linked to Ala-143 p53-mediated transcriptional activity. We should stress, however, that Fas/APO-1 expression is not absolutely dependent upon the presence or absence of the p53 protein. For example, Fas/APO-1 is not always expressed in wild-type p53-expressing cells (i.e., H460) and, reciprocally, can be detected in cells homozygously deleted for the p53 allele (14) . These findings imply that the Fas/APO-1 gene is controlled at multiple levels, some of which involve p53. Although the effects we observed are probably due to the strong expression of p53 under the influence of the cytomegalovirus promoter/enhancer, other physiologic stimuli VOL. 15, 1995 p53 INDUCES Fas/APO-1 EXPRESSION 3037
on July 5, 2017 by guest http://mcb.asm.org/ known to induce p53, such as irradiation and chemotherapeutic agents, have also been shown to enhance Fas/APO-1 expression and/or alter the sensitivity to anti-Fas mediated killing (14, 47) . The process of Fas/APO-1 induction by Ala-143 p53 was shown to occur in the absence of de novo protein synthesis, suggesting that Fas/APO-1 is a direct transcriptional target for p53. That Ala-143 p53 induced Fas/APO-1 mRNA after cycloheximide pretreatment and culture at the permissive temperature was not completely unexpected, given the stability of the p53 mutant protein and the known enhancement of DNA binding and transcriptional activity of this mutant at 32.5ЊC (81, 83) . In support of our observation that p53 can enhance Fas/APO-1 gene expression, sequence analysis of the human Fas/APO-1 promoter has revealed the presence of a p53CON element (26) approximately 1.3 kb upstream in the 5Ј-flanking region of this gene (6, 10) . Our laboratory is currently undertaking experiments to further define the p53-mediated regulation of Fas/APO-1 and determine p53 binding within the promoter and intronic sequences of human Fas/APO-1.
The measurements of transcriptional activity, cytoplasmic mRNA, and cell surface protein indicate that Ala-143 p53-mediated Fas/APO-1 gene expression in K562 cells is controlled by at least two regulatory steps. Northern blot analyses revealed that Fas/APO-1 mRNA was detectable at low levels in K562 Ala-143 cells maintained at 37.5ЊC and that expression was markedly upregulated upon culture at 32.5ЊC. Parental K562 cells, on the other hand, failed to express Fas/APO-1 mRNA when cultured at either temperature. Nuclear run-on assays confirmed these findings; K562 par cells did not demonstrate Fas/APO-1 expression, whereas Ala-143-containing cells showed transcriptional activation of this gene. These studies strongly support the premise that induction of Fas/APO-1 mRNA is transcriptional in nature and dependent on the presence of Ala-143 p53. In light of the levels of mature Fas/APO-1 mRNA accumulation and cell surface protein expression detected at the permissive temperature, it was somewhat surprising that Ala-143 cells shifted from the nonpermissive to the permissive temperature demonstrated only a modest increase (1.4-fold on average in three experiments) in the transcriptional rate of Fas/APO-1 synthesis. Although alterations in mRNA stability could account for this apparent disparity, we were unable to discern changes in Fas/APO-1 mRNA half-lives in Ala-143 K562 cells maintained at 37.5ЊC compared with those cultured at 32.5ЊC. Our in vitro transcription studies did not address possible differences in Fas/APO-1 transcriptional elongation between Ala-143 K562 cells cultured at the permissive and nonpermissive temperatures. Thus, it is conceivable that while transcriptional initiation was roughly equivalent at both temperatures, elongation and synthesis of full-length mRNA transcripts differed. Nuclear run-on assays performed with both 5Ј and 3Ј Fas/APO-1 cDNA probes will be required to test this hypothesis. Alternately, other posttranscriptional events (other than mRNA stability) may contribute to the Fas/APO-1 mRNA accumulation observed at the permissive temperature. Despite the apparent complexity regulating Fas/ APO-1 cell surface expression, it is clear that the initial event involves transcriptional activation of the Fas/APO-1 gene in the presence of Ala-143 p53.
Because wild-type p53 activity can induce growth arrest in some cell types, we explored whether the induction of Fas/ APO-1 was a consequence of the ability of p53 to alter the cell cycle rather than an effect attributable to p53 expression. The simultaneous analysis of cell cycle and cell surface Fas/APO-1 expression revealed that despite marked changes in cell cycle profile (increased G 1 and G 2 /M with decreased S phase relative to Ala-143-containing cells maintained at 37.5ЊC), Ala-143-transfected cells cultured at the permissive temperature showed enhanced Fas/APO-1 expression throughout the cell cycle without preferential display in G 1 or G 2 /M. Whether Fas/APO-1 expression is normally expressed at a particular point in the cell cycle cannot be inferred from these studies, because p53 is constitutively expressed under the cytomegalovirus promoter used for these experiments.
Although Fas/APO-1 can be induced in response to cellular activation (or as shown here by wild-type p53 activity), expression of Fas/APO-1 is not predictive of an apoptotic response initiated by specific antibody engagement. The dissociation of Fas/APO-1 function and expression has been observed in normal and malignant lymphocytes (52, 68) as well as in nonhematopoietic tumors (51, 78) . For example, Fas/APO-1 expression is observed on both resting and activated human lymphocytes, although sensitivity to anti-Fas-mediated apoptosis is restricted only to cells which have been chronically stimulated (52) . It is not particularly surprising, therefore, that Ala-143 K562 cells failed to undergo anti-Fas-triggered apoptosis despite expression of Fas/APO-1. Importantly, ongoing studies in our laboratories demonstrate that p53-driven Fas/ APO-1 upregulation can result in a functional Fas/APO-1 protein in several other cell types including H460 and H358 (14) . The nature of the K562 resistance is currently unknown; however, previous experimental evidence has documented the role of protective proteins such as manganese superoxide dismutase (29) and bcl-2 (30) in anti-Fas resistance in other cell types. Another potentially interesting, albeit unexplored, candidate mediating K562 resistance to anti-Fas is the Bcr-Abl fusion protein (42) .
The role of apoptosis in the pathogenesis of malignant disease has been underscored by recent observations that p53 can induce apoptosis (32, 54, 56, 60, 62, 70, 79) and that p53-dependent apoptosis can be a critical regulator of tumorigenesis (65) . Recently, the molecular mechanisms underlying p53-induced apoptosis have been suggested to involve either alterations in cellular genes necessary for survival or the direct participation of p53 in DNA repair or apoptotic DNA cleavage (8) . Thus, several investigators have demonstrated that the 26-kDa intracellular integral membrane protein bcl-2 and its recently identified molecular antagonist bax (50) are transcriptional targets for p53; bcl-2 levels are negatively regulated while bax is positively regulated by p53 (46) . Additionally, p53 has been postulated to control apoptotic cell death by participating in DNA repair (36) or intranucleosomal cleavage of DNA (76) . In support of the latter hypothesis, Caelles et al. have demonstrated that p53-dependent apoptosis can occur in the absence of transcriptional activation of p53 target genes in the somatotropic progenitor cell line GHFT1 (8) . Our data suggest a previously unrecognized possibility-that p53 can transcriptionally activate target genes known to induce apoptosis. It appears that multiple mechanisms are involved in the regulation of apoptosis in various cell types, namely, p53 dependent (independent of or dependent on p53-mediated transcription) and p53 independent. It is conceivable that autocrine or paracrine apoptotic cell death could be initiated in some cell types following p53-driven upregulation of Fas/ APO-1 and interaction with the natural Fas/APO-1 ligand (64) . Indeed, p53 may play a critical role in the recently documented Fas/Fas-ligand-dependent ''activation-induced'' apoptosis of lymphoid cells (3, 48, 59, 75) . 
